At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 13 enrolled
Drug / intervention
BIA 2-093 +1 moredrug
Likely dose
BIA 2-093 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating BIA 2-093 and Oxcarbazepine for Epilepsy. Completed, enrolled 13 participants across 1 site.
Detailed Summary
To investigate the pharmacokinetics of a single 900 mg oral dose of BIA 2-093 and a single 900 mg oral dose of Oxcarbazepine in healthy volunteers and to assess the tolerability of a single 900 mg dose of BIA 2-093 and Oxcarbazepine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesPortugal
Collaborators--
Timeline
Phase 1CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2002
Primary CompletionApr 2002
First PostedSep 2012
TodayJul 2026
First PostedSep 5, 2012
Enrollment StartMar 1, 2002
Primary CompletionApr 1, 2002
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 13.8 years ago
Interventions
BIA 2-093drug
Tablets containing BIA 2-093 in doses of 300 and 600 mg
Oxcarbazepinedrug
Tablets containing 300 mg and 600 mg of Trileptal®